Carbimazole and phenobarbital interaction in cats: reduced efficacy
Published: · Updated:
Phenobarbital may reduce carbimazole efficacy in cats. The Felinta label gives no effect size or automatic dose correction; clinical follow-up matters.
Short answer
Phenobarbital may reduce carbimazole clinical efficacy in cats, according to the Felinta label. The interaction sentence does not quantify the effect or describe a detailed mechanism. A change in thyroid control needs individual veterinary assessment; the warning alone does not select a new dose or establish the cause of a laboratory result. [1]
Compare the evidence
| Source and design | Population or scope | Finding | Limits |
|---|---|---|---|
| Official Felinta label [1] | Cats receiving prolonged-release carbimazole | Concurrent phenobarbital may reduce carbimazole clinical efficacy. | No quantified effect or detailed mechanism; the prodrug description does not identify the step phenobarbital changes. |
| Carney et al., 2016 — AAFP guideline [2] | Feline hyperthyroidism follow-up | Provides clinical context for thyroid disease, monitoring and comorbidities. | Abstract reviewed; no direct measurement of this pair. Canine induction findings cannot replace feline interaction data. |
Can phenobarbital reduce carbimazole efficacy in a cat?
Yes, according to Felinta's cat label: concomitant phenobarbital may reduce carbimazole clinical efficacy. The wording identifies a possible effect, without predicting treatment failure in every cat or specifying a dose increase. [1]
Does the label provide a measured size or mechanism for this interaction?
No. The interaction sentence gives no effect size, incidence estimate or detailed mechanism. Verification confirms the warning's presence; it does not supply missing clinical measurements or justify importing a mechanism from another species. [1]
What should be considered if thyroid control changes?
Review clinical findings with total thyroxine, haematology and liver and kidney parameters, as described by Felinta. The interaction is relevant context but cannot establish the cause of a laboratory change or select a new dose. [1]
Can a prolonged-release tablet be split to make a small adjustment?
Felinta tablets must not be broken or crushed because this affects their sustained-release property. The interaction warning does not override that instruction. Other formulations require their own product-specific review. [1]
Would a different feeding time reliably remove the interaction?
No feeding or spacing correction is established in the cited interaction section. Felinta's separate instruction to keep administration consistent relative to feeding supports reliable product use; it is not a proven remedy for this combination. [1]
Does this justify stopping either medicine without veterinary review?
No. The warning identifies a reason for review, not an instruction to discontinue treatment. The veterinarian needs the actual products, indications, administration history and clinical follow-up to decide whether either regimen should change. [1]
Evidence appraisal
Felinta’s interaction sentence establishes a possible reduction in clinical efficacy, but gives no detailed biochemical mechanism, concentration change or treatment-failure rate. Its pharmacology section separately describes conversion of carbimazole to active thiamazole. That prodrug information helps explain the medicine; it is not proof of which step phenobarbital changes. The mechanism for this exact pair remains unspecified in the cited passage. [1]
The 2016 AAFP guideline places hyperthyroidism treatment in the context of comorbid disease and monitoring. That is relevant to interpreting a changing clinical course, but the reviewed guideline abstract is not an interaction experiment. In particular, canine phenobarbital enzyme-induction evidence cannot be silently substituted for direct feline measurements of carbimazole or thiamazole exposure. The interaction conclusion here rests on the cat-product label. [2] [1]
Clinical interpretation and follow-up
Felinta calls for clinical assessment with TT4, haematology and liver and kidney parameters. Record formulation, intact-tablet administration, consistency relative to feeding and phenobarbital history. These source-informed review items contextualize follow-up; they do not prove an interaction caused a result. [1]
A change in thyroid control warrants interpretation alongside administration history and the wider disease course. The prolonged-release tablet's handling instructions remain applicable. The interaction warning supplies no new dose and no feeding-based correction. [1] [2]
Questions for veterinary review
Editorial discussion checklist for your veterinarian:
- Confirm the carbimazole formulation and phenobarbital history for the same cat.
- Review clinical response and veterinarian-requested thyroid and other laboratory results together.
- Keep formulation and feeding instructions separate from an unsupported interaction correction.
Catalogue review status and evidence limits
The catalogue records contain verified direct evidence (cat): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.
A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.
Evidence sources
Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.
- VMD: Felinta 10 mg Prolonged-release Tablets for Cats — Summary of Product Characteristics
Evidence type: Official product label. Revised December 2024. 4.8, interactions; 4.9, administration and follow-up; 5.1–5.2, pharmacology. Page 4, Page 5, Page 6, Page 7. Source checked: . Open official VMD source
- 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism.
Carney HC et al. J Feline Med Surg. 2016;18(5):400-416. Evidence type: Consensus guideline. Review scope: Abstract and bibliographic record. Source checked: . Open research source
Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.